Treatment of Hypertension With Adalat® in Combination With Other Drugs

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT01118286
First received: May 5, 2010
Last updated: June 26, 2012
Last verified: June 2012

May 5, 2010
June 26, 2012
January 2010
Not Provided
Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients [ Time Frame: After three months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01118286 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Hypertension With Adalat® in Combination With Other Drugs
AdADOSE - Antihypertensive Treatment With Adalat® in Different Doses and Combination Therapy

To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy

Hypertension
Drug: Nifedipine (Adalat, BAYA1040)
Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
Group 1
Intervention: Drug: Nifedipine (Adalat, BAYA1040)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4497
September 2011
Not Provided

Inclusion Criteria:

  • Previously untreated hypertensive patients starting with combination therapy containing nifedipine or
  • Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy

Exclusion Criteria:

  • None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Bahrain,   Egypt,   Jordan,   Lebanon,   Morocco,   Oman,   Pakistan,   Qatar,   Russian Federation,   Saudi Arabia,   United Arab Emirates
 
NCT01118286
14296, AL0701, AdADOSE
No
Medical Affairs Therapeutic Area Head, Bayer Healthcare AG
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP